Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter radiation may be just as effective for breast cancer patients

NCT ID NCT01413269

Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 720 women with early-stage breast cancer who had a lumpectomy. They were split into two groups: one got standard daily radiation for several weeks, the other got a shorter course of higher-dose radiation. The goal was to see if the shorter treatment works just as well to prevent the cancer from coming back, with similar side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

720 people

The number who actually took part.

Start date

Jun 2010

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. KPS\>=60 2. histology confirmed invasive breast cancer 3. received breast conservative surgery(wide local excision and axilla dissection, or axillary sentinel node biopsy if sentinel node is negative) 4. surgical margins negative 5. primary tumor ≤5cm in the largest diameter 6. no internal mammary node or supraclavicular node metastases or distant metastasis 7. can tolerate chemotherapy,hormone therapy (if needed) and radiotherapy 8. for patients not need chemotherapy，enrollment date is required no more than 8 weeks from surgery date 9. for patients with chemotherapy first,enrollment date is required no more than 8 weeks from the last date of chemotherapy 10. patients signed written inform consent form Exclusion Criteria: 1. ductal carcinoma in situ 2. prior neoadjuvant chemotherapy 3. prior breast cancer history 4. bilateral breast cancer 5. pregnant or during lactation 6. prior or concomitant malignant tumor excluded skin cancer(not malignant melanoma) and cervix carcinoma in situ 7. active collagen vascular disease 8. prior neoadjuvant hormone therapy 9. immediate ipsilateral breast reconstruction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Beijing hospital

    Beijing, Beijing Municipality, 100730, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, 100021, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.